Pfizer's August Performance Driven by Strong Earnings and Regulatory Advances
In a surprising turn, Pfizer (ticker: PFE) outperformed its pharmaceutical peers in August with nearly 14% gains. This was largely due to better-than-expected second-quarter earnings reported on Aug. 4, where revenue rose 3% year-over-year to $15 billion and non-GAAP net income reached $4.4 billion or $0.77 per share—both exceeding analyst expectations. Pfizer also raised its full-year revenue guidance for non-COVID products while maintaining its EPS forecast between $2.80 and $3. The company's top-selling drug, Eliquis, contributed significantly to the growth with a 19% year-over-year sales increase. However, concerns remain about Eliquis facing generic competition soon. Regulatory advancements also played a role in Pfizer’s strong performance. In August, it received validation from the European Medicines Agency for its next-generation Lyme disease treatment and FDA approval of an updated version of its Comirnaty vaccine developed with BioNTech.
Tickers: $PFE
Topics: Earnings Reports Patent Cliff Pharmaceuticals Revenue Growth